CD45 antigen negativity in T-lineage ALL correlates with PTPRC mutation and sensitivity to a selective JAK inhibitor

Br J Haematol. 2015 Dec;171(5):884-7. doi: 10.1111/bjh.13448. Epub 2015 Apr 8.

Authors

Affiliations

¹ Haematology, Department of Cellular Biotechnologies and Haematology, Sapienza University, Rome, Italy.
² Centre for Human Genetics, KU Leuven, Leuven, Belgium.
³ Centre for the Biology of Disease, VIB, Leuven, Belgium.
⁴ Haematology, Department of Cellular Biotechnologies and Haematology, Sapienza University, Rome, Italy. guarini@bce.uniroma1.it.

PMID: 25854815
DOI: 10.1111/bjh.13448

No abstract available

Keywords: CD45 antigen; JAK1 mutation; PTPRC mutation; T-lineage acute lymphoblastic leukaemia; target therapy.

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / therapeutic use
Humans
Janus Kinase 1 / antagonists & inhibitors*
Leukemia-Lymphoma, Adult T-Cell / drug therapy*
Leukemia-Lymphoma, Adult T-Cell / genetics
Leukocyte Common Antigens / deficiency*
Leukocyte Common Antigens / genetics
Male
Middle Aged
Mutation / genetics*
Nitriles
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics*
Pyrazoles / therapeutic use
Pyrimidines

Substances

Antineoplastic Agents
Nitriles
Pyrazoles
Pyrimidines
ruxolitinib
JAK1 protein, human
Janus Kinase 1
Leukocyte Common Antigens
PTPRC protein, human